CEO Exclusive - IMU doses first patient in phase one trial, page-106

Biotech is littered with delays, that doesn't mean things are bad or wrong. Many punters were calling for Her-Vaxx Phase 2 results to be posted for 6+ months. When the results came back they were found to be statistically significant and passed their trial with a better response the the current SOC. The longer the wait in Her-Vaxx results just ended up providing better results on their trial drug.

IMU isn't a $1b company with a phase 1 trial. It is a company with no less than 5 current FDA approved trials in different stages. Some of these have great preclinical results and others are seeing great early results in the clinic.

You mention you will buy when the gap is filled. 8th of August will be a significant day for IMU and likely to see a spike in the SP as a result of providing results on one of our trials. Maybe having some skin in the game is a better idea now as the, "Break out gap" may never close